The NPR1 gene (Natriuretic Peptide Receptor 1), also known as NPR-A or guanylate cyclase 1, encodes the major receptor for atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). This receptor is a member of the natriuretic peptide receptor family and functions as a particulate (membrane-bound) guanylate cyclase that catalyzes the conversion of GTP to cyclic GMP (cGMP) upon ligand binding. NPR1 is expressed throughout the cardiovascular system, kidney, adrenal gland, and importantly, in various brain regions where it plays roles in cardiovascular regulation, fluid homeostasis, memory formation, and neuroprotection. The NO-cGMP and natriuretic peptide-cGMP pathways represent parallel but distinct signaling cascades that converge on similar downstream effectors, making NPR1 an important nexus for understanding cardiovascular-neural interactions in neurodegeneration. [@kuhn2016]
| Property | Value |
|----------|-------|
| **Gene Symbol** | NPR1 (NPR-A, GC-A) |
| **Full Name** | Natriuretic Peptide Receptor 1 / Guanylate Cyclase 1 |
| **Chromosomal Location** | 1q22 |
| **NCBI Gene ID** | 4880 |
| **OMIM ID** | 108012 |
| **Ensembl ID** | ENSG00000118445 |
| **UniProt ID** | P16066 |
| **Protein Class** | Receptor guanylate cyclase |
| **Aliases** | NPR1, NPRA, GC-A, ANPRA, Guanylate cyclase 1 |
| **Gene Family** | Natriuretic peptide receptors (NPR1, NPR2/NPR-B, NPR3/NPR-C) |
¶ Protein Structure and Function
NPR1 is a single-pass transmembrane receptor (~1057 amino acids) with distinct structural domains:
- Extracellular ligand-binding domain: N-terminal region that binds natriuretic peptides (ANP, BNP, CNP) with different affinities
- Transmembrane domain: Single α-helix that anchors the receptor in the plasma membrane
- Kinase-like domain: Intracellular domain with ATP-binding activity that regulates the guanylate cyclase domain
- Guanylate cyclase domain: C-terminal catalytic domain that produces cGMP from GTP
The extracellular domain shows highest affinity for ANP, followed by BNP, with CNP binding at lower affinity. The intracellular domain exists in an autoinhibited state in the absence of ligand, with ATP binding to the kinase-like domain enhancing ligand-mediated activation. [@potter2011]
NPR1 activation follows a ligand-binding-induced conformational change:
- Ligand binding: ANP, BNP, or CNP binds to the extracellular domain
- Conformational change: Ligand binding transmits a conformational change across the transmembrane domain
- Kinase domain activation: The intracellular kinase-like domain undergoes a structural change
- Cyclase activation: The guanylate cyclase domain becomes catalytically active
- cGMP production: GTP is converted to cGMP, initiating downstream signaling
The kinase-like domain plays a regulatory role, with ATP acting as a positive allosteric modulator that enhances ligand-dependent cGMP production.
NPR1-mediated cGMP production regulates multiple downstream effectors:
- cGMP-dependent protein kinases (PKG): PKG I and II phosphorylate various targets
- cGMP-regulated phosphodiesterases: Particularly PDE2 and PDE3
- cGMP-gated ion channels: Regulate calcium homeostasis
- Transcription factors: cGMP modulates gene expression through PKG and CREB
NPR1 is expressed in multiple brain regions:
- Hypothalamus: High expression in the supraoptic nucleus and paraventricular nucleus (regulating fluid balance)
- Thalamus: Moderate expression in various thalamic nuclei
- Circumventricular organs: High expression in areas lacking blood-brain barrier (organum vasculosum, subfornical organ)
- Hippocampus: Expression in CA1 and CA3 regions, dentate gyrus
- Cerebral cortex: Layer-specific expression in pyramidal neurons
- Cerebellum: Purkinje cell expression
- Brainstem: Expression in cardiovascular control centers
- Vascular system: Endothelial cells and vascular smooth muscle
- Heart: Atrial and ventricular myocytes
- Kidney: Glomerular mesangial cells, tubular cells
- Adrenal gland: Adrenal cortex (zona glomerulosa)
- Lung: Alveolar epithelial cells
Expression is modulated by physiological conditions, with increased expression during heart failure and certain neurological conditions. [@yamamoto2019]
NPR1 and natriuretic peptides are increasingly recognized in AD pathogenesis:
-
ANP alterations: Atrial natriuretic peptide levels are altered in AD patients, with some studies showing decreased ANP in cerebrospinal fluid. The peptide has protective effects against Aβ toxicity through cGMP-dependent mechanisms. [@abdulle2013]
-
Amyloid-β interactions: ANP can protect neurons against Aβ-induced toxicity through NPR1-mediated cGMP signaling. This involves activation of PKG, which phosphorylates targets that reduce oxidative stress and apoptosis. [@chang2017]
-
Neurovascular function: NPR1 in endothelial cells regulates cerebral blood flow. Dysregulated natriuretic peptide signaling contributes to neurovascular dysfunction in AD.
-
Memory and synaptic function: cGMP signaling through NPR1 is involved in memory consolidation and synaptic plasticity. NPR1 activation can enhance long-term potentiation (LTP).
-
Tau pathology: Preliminary evidence suggests natriuretic peptide signaling may interact with tau phosphorylation pathways through cGMP-dependent kinases.
[@takamura2017] demonstrated that ANP can ameliorate memory deficits in animal models of AD through NPR1-mediated mechanisms.
NPR1 signaling is relevant to PD through several mechanisms:
-
Dopaminergic neuron survival: NPR1 is expressed in dopaminergic neurons and activation can protect against dopaminergic toxicity. cGMP-mediated signaling has neuroprotective effects in PD models. [@morris2020]
-
Neuroinflammation: Natriuretic peptide signaling has anti-inflammatory effects, potentially modulating the neuroinflammation central to PD progression.
-
Mitochondrial function: NPR1-cGMP signaling modulates mitochondrial function and can protect against oxidative stress, a key factor in PD pathogenesis.
-
Blood-brain barrier: NPR1 in endothelial cells regulates BBB function, potentially affecting drug delivery and disease progression.
[@ogawa2021] demonstrated NPR1 expression in dopaminergic neurons and its role in neuroprotection.
¶ Stroke and Cerebral Ischemia
NPR1 activation has protective effects in stroke:
- Ischemic injury: NPR1 activation reduces infarct size and improves functional recovery in experimental stroke models
- Blood flow: cGMP-mediated vasodilation improves cerebral perfusion
- Apoptosis inhibition: NPR1 activation reduces apoptotic cell death
- Angiogenesis: Promotes blood vessel formation post-injury
[@yang2021] demonstrated that NPRA (encoded by NPR1) provides neuroprotection in ischemic stroke through cGMP-PKG signaling.
- Heart failure with preserved ejection fraction: Associated with cognitive decline through altered cerebral perfusion
- Vascular cognitive impairment: Natriuretic peptide signaling affects cerebrovascular function
- Depression: Altered natriuretic peptide levels observed in depression
flowchart TD
subgraph Natriuretic_Peptides
A["ANP<br/>Atrial Natriuretic Peptide"]
B["BNP<br/>Brain Natriuretic Peptide"]
C["CNP<br/>C-type Natriuretic Peptide"]
end
A --> D["NPR1 / NPR-A<br/>Guanylate Cyclase 1"]
B --> D
C --> D
D --> E["cGMP Production"]
E --> F["PKG Activation"]
E --> G["PDE Regulation"]
E --> H["CNG Channels"]
F --> I1["CREB Phosphorylation"]
F --> I2["Apoptosis Inhibition"]
F --> I3["Vasodilation"]
G --> J["Ca²⁺ Modulation"]
H --> K["Neural Excitability"]
I1 --> L1["Gene Transcription<br/>Neuroprotection"]
I2 --> L2["Survival Pathways"]
I3 --> L3["Blood Flow<br/>BBB Function"]
M["Disease States"] --> N1["AD: ANP protects vs Aβ toxicity"]
M --> N2["PD: NPR1 protects dopaminergic neurons"]
M --> N3["Stroke: NPR1 reduces infarct size"]
-
cGMP-dependent protein kinase (PKG): Major effector mediating most NPR1 effects
- CREB phosphorylation
- BAD phosphorylation (anti-apoptotic)
- eNOS activation
-
Phosphodiesterases: PDE2, PDE3 regulated by cGMP
-
Ion channels: cGMP-gated channels affecting neuronal excitability
- Natriuretic peptide analogs: Synthetic ANP or BNP analogs for neuroprotection
- cGMP analogs: Direct cGMP or PKG activators
- PDE inhibitors: Enhance cGMP signaling (particularly PDE5 inhibitors)
- Gene therapy: AAV-mediated NPR1 expression
- Blood-brain barrier penetration
- Receptor desensitization
- Off-target cardiovascular effects
- Timing of intervention
- Natriuretic peptides (NPPA, NPPB, NPPC): Ligands
- PDE5A: cGMP metabolism
- PKG1A/PKG1B: Major effector kinases
- eNOS: Cross-talk with NO signaling
- Natriuretic peptide signaling pathway
- cGMP-dependent signaling pathway
- Cardiovascular regulation
- Neuroprotection pathways
- Npr1 knockout mice: Show cardiac hypertrophy, hypertension, and reduced lifespan
- Transgenic overexpression: Protection in various injury models
- Conditional knockouts: Brain-specific deletion reveals roles in memory
- Potter LR, et al., Natriuretic peptide receptors, NPR-A and NPR-B (2011)
- Kuhn M, Molecular physiology and pathophsyiology of natriuretic peptides (2016)
- Calabrese V, et al., cGMP and neurodegeneration: Therapeutic potential (2019)
- Abdulle A, et al., Atrial natriuretic peptide in Alzheimer's disease (2013)
- Chang CP, et al., Atrial natriuretic peptide protects against beta-amyloid toxicity (2017)
- Morris LA, et al., Natriuretic peptide signaling in Parkinson's disease (2020)
- Yang J, et al., NPRA and neuroprotection in ischemic stroke (2021)
- Johnson ML, et al., NPPA and cardiovascular aging (2018)
- Yamamoto K, et al., Natriuretic peptides and their receptors in brain (2019)
- Taniguchi M, et al., C-type natriuretic peptide in the brain (2016)
- O'Connor CM, et al., NPR1 and heart failure (2015)
- Saward L, et al., Natriuretic peptides in the cerebral circulation (2007)
- Schirer T, et al., NPRA in astrocyte function and neuroprotection (2020)
- Kaneki M, et al., C-type natriuretic peptide and neurodegeneration (2018)
- Ogawa K, et al., NPRA expression in dopaminergic neurons (2021)
- Chen Y, et al., Natriuretic peptide receptor C and neurodegeneration (2019)
- Takamura Y, et al., ANP and amyloid-beta interaction in Alzheimer's models (2017)
- Fischer T, et al., NPR1 gene variants and cardiovascular traits (2018)